Search Results for: NF2

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CCND2 cyclin D2
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Testicular cancer
CD44 CD44 molecule (Indian blood group)
  • Degradation of the extracellular matrix
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Hyaluronan uptake and degradation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Bivatuzumab
  • Hyaluronic acid
  • Gastric cancer
EMD emerin
  • Nuclear Envelope Breakdown
  • Initiation of Nuclear Envelope (NE) Reformation
  • Depolymerisation of the Nuclear Lamina
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Emery-Dreifuss muscular dystrophy
GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
PDGFRA platelet derived growth factor receptor alpha
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Imatinib-resistant PDGFR mutants
  • Sunitinib-resistant PDGFR mutants
  • Regorafenib-resistant PDGFR mutants
  • Sorafenib-resistant PDGFR mutants
  • PDGFR mutants bind TKIs
  • Becaplermin
  • Imatinib
  • Sunitinib
  • XL820
  • Olaratumab
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Ripretinib
  • Glioma
SLC9A3R1 SLC9A3 regulator 1
  • Nephrolithiasis/osteoporosis, hypophosphatemic
TERT telomerase reverse transcriptase
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Zidovudine
  • Grn163l
  • Tertomotide
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2
  • Netrin-1 signaling
AMOT angiomotin
AMOTL2 angiomotin like 2
  • Signaling by Hippo
ARNT aryl hydrocarbon receptor nuclear translocator
  • Regulation of gene expression by Hypoxia-inducible Factor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
AURKA aurora kinase A
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Regulation of PLK1 Activity at G2/M Transition
  • SUMOylation of DNA replication proteins
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • AURKA Activation by TPX2
  • Interaction between PHLDA1 and AURKA
  • Phosphonothreonine
  • AT9283
  • CYC116
  • Alisertib
  • SNS-314
  • Cenisertib
  • Enzastaurin
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • AKI-001
  • 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
  • 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
  • N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
  • N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
  • 2-(1H-pyrazol-3-yl)-1H-benzimidazole
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • Fostamatinib
  • MLN8054
BDKRB1 bradykinin receptor B1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Ramipril
  • Captopril
  • Zinc
  • Enalaprilat
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
BECN1 beclin 1
  • Macroautophagy
  • Ub-specific processing proteases
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Estradiol
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
BYSL bystin like
  • Major pathway of rRNA processing in the nucleolus and cytosol
CBLC Cbl proto-oncogene C
CCNB1IP1 cyclin B1 interacting protein 1
CDK6 cyclin dependent kinase 6
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Alvocidib
  • (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
  • Fisetin
  • Palbociclib
  • Ribociclib
  • Abemaciclib
CDKN2C cyclin dependent kinase inhibitor 2C
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
DACH1 dachshund family transcription factor 1

Page 2 out of 4 pages